Landscapes / Targets
IL-17A
12 drugs act on IL-17A, in 33 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs12
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
Approved | 21 Dec 2026Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 21 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis and 5 more | ||||
| Open drug page | |||||
— |
3SBio · Public 1530.HK |
Approved in China | 14 Jan 2027Phase 3 trial completes | ||
| Next date | 14 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Axial Spondyloarthritis, Ankylosing Spondylitis and 1 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Hengrui · Public 600276.SS |
Approved in China | Mar 2027Phase 4 trial completes | ||
| How it works | An antibody | ||||
| Next date | Mar 2027 · Phase 4 trial completes | ||||
| Also tested for | Psoriatic Arthritis, Moderate to Severe Plaque Psoriasis and 2 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 8 Feb 2028Phase 4 trial completes | |||
| How it works | An antibody | ||||
| Next date | 8 Feb 2028 · Phase 4 trial completes | ||||
| Also tested for | Autoimmunity, Inflammation, Non-radiographic Axial Spondyloarthritis and 3 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Eli Lilly · Public LLY |
Approved | — | ||
| How it works | An antibody | ||||
| Also tested for | Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis | ||||
| Open drug page | |||||
Monoclonal antibody |
Phase 3 | 4 Jan 2027Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 4 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Arthritis, Psoriatic, Hidradenitis Suppurativa | ||||
| Open drug page | |||||
— |
Sinocelltech · Public 688520.SS |
Phase 2 | 12 Mar 2027Phase 2 trial completes | ||
| Next date | 12 Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Hidradenitis Suppurativa (HS) | ||||
| Open drug page | |||||
Multi-specific immunoglobulin |
Phase 2 | 17 May 2027Phase 2 trial completes | |||
| How it works | An antibody built to latch onto two or more targets at once | ||||
| Next date | 17 May 2027 · Phase 2 trial completes | ||||
| Also tested for | Atopic Dermatitis, Non-cystic Fibrosis Bronchiectasis and 1 more | ||||
| Open drug page | |||||
— |
Huahai Pharmaceutical (Huaota) · Public 600521.SS |
Phase 1/2 | — | ||
| Also tested for | Hidradenitis Suppurativa, Acne Vulgaris | ||||
| Open drug page | |||||
SB35not checked |
— |
Phase 1 | 9 Jun 2027Phase 1 trial completes | ||
| Next date | 9 Jun 2027 · Phase 1 trial completes | ||||
| Open drug page | |||||
— |
Akeso · Public 9926.HK |
Phase 1 | — | ||
| Open drug page | |||||
CT-P52not checked |
— |
Phase 1 | — | ||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 10 of 12 drugs. The other 2 are marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026